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Abstract: Loss-of-function mutations of NaV1.7 lead to congenital insensitivity to pain, a rare
condition resulting in individuals who are otherwise normal except for the inability to sense pain,
making pharmacological inhibition of NaV1.7 a promising therapeutic strategy for the treatment
of pain. We characterized a novel mouse model of NaV1.7-mediated pain based on intraplantar
injection of the scorpion toxin OD1, which is suitable for rapid in vivo profiling of NaV1.7 inhibitors.
Intraplantar injection of OD1 caused spontaneous pain behaviors, which were reversed by co-injection
with NaV1.7 inhibitors and significantly reduced in NaV1.7´{´ mice. To validate the use of the
model for profiling NaV1.7 inhibitors, we determined the NaV selectivity and tested the efficacy
of the reported NaV1.7 inhibitors GpTx-1, PF-04856264 and CNV1014802 (raxatrigine). GpTx-1
selectively inhibited NaV1.7 and was effective when co-administered with OD1, but lacked efficacy
when delivered systemically. PF-04856264 state-dependently and selectively inhibited NaV1.7 and
significantly reduced OD1-induced spontaneous pain when delivered locally and systemically.
CNV1014802 state-dependently, but non-selectively, inhibited NaV channels and was only effective in
the OD1 model when delivered systemically. Our novel model of NaV1.7-mediated pain based on
intraplantar injection of OD1 is thus suitable for the rapid in vivo characterization of the analgesic
efficacy of NaV1.7 inhibitors.
Keywords: OD1; NaV1.7; PF-04856264; CNV1014802; raxatrigine; GpTx-1; pain
1. Introduction
Nine voltage-gated sodium channel subtypes have been described to date (NaV1.1–NaV1.9),
several of which are implicated as causative contributors to pain. Of particular interest is NaV1.7,
as loss-of-function mutations in humans lead to congenital insensitivity to pain, a rare condition
that results in the inability to sense pain [1,2]. This makes pharmacological inhibition of NaV1.7 an
exciting therapeutic strategy for the treatment of a wide range of pain types, including inherited
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erythromelalgia and paroxysmal extreme pain disorder, two conditions whose pathophysiology
arises from NaV1.7 gain-of-function mutations. Accordingly, the development of NaV1.7 inhibitors is
being actively pursued by the pharmaceutical industry [3]. NaV1.7 selectivity is key to developing
more effective analgesics as activity at major off-targets, including the skeletal muscle isoform
NaV1.4, the cardiac isoform NaV1.5, as well as neuronal isoforms NaV1.1, NaV1.2 and NaV1.6, is
likely to impact the therapeutic window and cause dose-limiting adverse effects [4–6]. However,
achieving sufficient selectivity for NaV1.7 over the other NaV isoforms has proven challenging due
to the high sequence homology within the NaV family [7]. Despite this challenge, several small
molecules with reported NaV1.7 selectivity are currently undergoing clinical development, including
PF-05089771 (Pfizer) and CNV1014802 (Convergence Pharmaceuticals) [8]. In addition to small
molecules, venom-derived peptides are proving to be an alternate source for NaV1.7 inhibitors, with
several spider peptides, including GpTx-1, Huwentoxin-IV and ProTx-II, reported to have some NaV1.7
selectivity [9–11]. Evaluating the analgesic efficacy of this increasing number of NaV1.7-selective
compounds in relevant pre-clinical models of pain is a crucial translational step to clinical success.
However, the pathophysiological basis of most commonly used animal models is multi-factorial,
making selection of the best disease model for rapid efficacy profiling of NaV1.7 inhibitors challenging.
We thus sought to characterize a novel animal model of NaV1.7-mediated pain that is suitable for the
rapid in vivo profiling of the analgesic efficacy of NaV1.7 inhibitors. As gain-of-function mutations of
NaV1.7 in humans are associated with a range of painful syndromes [12,13], we hypothesized that
intraplantar administration of the NaV1.7 activator OD1 could be used as a pharmacological tool to
establish a NaV1.7-mediated mouse model of pain.
OD1 is a scorpion toxin isolated from the venom of the Iranian yellow scorpion (Odontobuthus
doriae) that potently enhances the activity of NaV1.7 by inhibiting channel fast inactivation and
increasing peak current with an EC50 between 4 and 8 nM [14,15]. OD1 also has activity at NaV1.4
(EC50 = 10 nM) and NaV1.6 (EC50 = 30–47 nM); however, it is 1000-fold selective (EC50 > 1 µM) over
NaV1.1, NaV1.2, NaV1.3, NaV1.5 and NaV1.8 [14,15]. Consistent with its in vitro pharmacological
activity, intraplantar administration of OD1 elicited pain behaviors, including licking and flinching of
the hind paw, and we have previously used this model to assess the analgesic effects of ProTx-III [16].
The aim of this study was to characterize the OD1 mouse model of pain and to validate the use
of this model by testing the efficacy of several reported selective NaV1.7 inhibitors, including the
spider peptide GpTx-1, PF-04856264 (as the structure of clinical candidate PF-05089771 is not publicly
available) [17] and the clinical candidate CNV1014802 (raxatrigine). As the full pharmacological
activity of these inhibitors is not reported, we determined their selectivity at NaV1.1–NaV1.8 and the
mode of action at NaV1.7 using functional assays.
2. Results
2.1. OD1 Has Mixed α/β-Scorpion Toxin Activity at NaV1.7 at High Concentrations
OD1 was previously described as an α-scorpion toxin that enhances peak NaV1.7 current
expressed in oocytes with a minor effect on the voltage dependence of channel activation or
inactivation [14]. However, this effect is difficult to reconcile with the induction of spontaneous
pain behavior in vivo, and we thus sought to evaluate the electrophysiological effects at NaV1.7 at
concentrations that elicit robust spontaneous pain behaviors in mice (300 nM, see below). At a
concentration of 300 nM, OD1 enhanced peak inward current and delayed inactivation, resulting
in persistent current (Figure 1A,B), consistent with previously observed effects [14]. OD1 (300 nM)
enhanced peak current with a leftward shift to more hyperpolarized potentials (Figure 1C). OD1
(300 nM) resulted in a small, non-significant shift in the V50 of inactivation for hNav1.7 peak
current, while a significant shift in V50 of inactivation was observed for the late current 10 ms after
depolarization (Figure 1D; V50 of inactivation: control, ´58.54 ˘ 0.23 mV; OD1peak, ´57.78 ˘ 0.37;
OD1late, ´52.71 ˘ 0.49). Although the V50 of inactivation is statistically unchanged at peak current,
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a significant fraction of hNav1.7 channels remain in the open state in the presence of OD1 (300 nM),
even at conditioning potentials that completely inactivate untreated channels, as can be seen by the
significantly increased slope of the voltage of inactivation (Figure 1D; kh control = 6.07 ˘ 0.20 mV; kh
OD1peak = 10.54 ˘ 0.33; kh OD1late = 11.45 ˘ 0.44; p < 0.05). Consistent with previous reports of mixed
α/β toxin pharmacology on NaV1.4 and NaV1.6, a significant hyperpolarizing shift V50 of activation
of ´12 mV at NaV1.7 was observed in the presence of OD1 (300 nM) compared to control conditions
(Figure 1E; V50 of activation: control, ´22.47 ˘ 0.47; OD1, ´34.50 ˘ 0.58; p < 0.05). OD1 (300 nM) also
delayed fast inactivation at more depolarized membrane potentials (Figure 1F).
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Figure 1. Activity of OD1 in CHO cells heterologously expressing hNaV1.7 assessed by automated 
patch clamping. Representative trace of sodium currents (A) before and (B) after addition of 300 nM 
OD1 elicited by depolarizing steps between −100 and +70 mV in 10-mV increments. The red trace 
highlights the depolarizing step to 0 mV. OD1 enhanced peak inward current and delayed 
inactivation, resulting in persistent current. (C) Current-voltage (IV) relationship before and after the 
addition of OD1 (300 nM). OD1 enhanced peak current with a leftward shift to more hyperpolarized 
potentials. (D) The voltage dependence of fast inactivation. OD1 significantly shifted the voltage 
dependence of fast inactivation for the late current 10 ms after depolarization (V50: control,  
−58.54 ± 0.23 mV; OD1peak, −57.78 ± 0.37; OD1late, −52.71 ± 0.49). (E) Voltage dependence of activation. 
OD1 shifted the voltage dependence of activation to a more hyperpolarized potential (V50: control, 
−22.47 ± 0.47; OD1 (300 nM), −34.50 ± 0.58). (F) Time of decay (τ) for inactivating current plotted versus 
test potential. OD1 (300 nM) delays fast inactivation at more depolarized membrane potentials.  
* p < 0.001 compared to the control. Data are presented as the mean ± SEM, n = 7. 
2.2. OD1 Causes Spontaneous Action Potential Firing in A- and C-Fibers 
To assess the effect of pharmacological NaV1.7 activation on A- and C-fibers, we tested OD1 
using the mouse skin-saphenous nerve preparation. Consistent with the crucial role of NaV1.7 in 
regulating excitability, the application of OD1 to the receptive fields of peripheral sensory neurons 
led to spontaneous firing of action potentials in some fibers, with 57% of A-fibers tested (Figure 2A,B; 
control 0 ± 0 and OD1 (30 nM) 13 ± 7 action potentials/2 min; n = 7) and 29% of C-fibers tested firing 
spontaneously (Figure 2C,D; control 1 ± 0.6 and OD1 (30 nM) 8 ± 5 action potentials/2 min; n = 7) in 
the presence of OD1. 
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Figure 2. Effects of NaV1.7 activation by OD1 on A- and C-fibers using the mouse skin-saphenous 
nerve preparation. (A) OD1 caused spontaneous firing of action potentials in 57% of the A-fibers 
tested (action potentials/2 min: control, 0 ± 0; OD1 (30 nM), 13 ± 7; n = 7). (B) Action potentials plotted 
as a function of instantaneous firing frequency from an A-fiber before and after perfusion of OD1. 
Each point represents a single action potential, with the position on the y-axis indicating the frequency 
relative to the preceding action potential. (C) OD1 caused spontaneous firing of action potentials in 
29% of the C-fibers tested (action potentials/2 min: control, 1 ± 0.6; OD1 (30 nM), 8 ± 5; n = 7).  
(D) Action potentials plotted as a function of instantaneous firing frequency from a C-fiber before and 
after perfusion of OD1. Each point represents a single action potential, with the position on the y-axis 
indicating the frequency relative to the preceding action potential. 
2.3. Intraplantar Injection of OD1 Causes Spontaneous Pain Behavior in Mice Mediated Through NaV1.7 
To assess the effect of OD1 on pain behaviors in mice, we chose the intraplantar route of 
administration, as this route delivers the peptide directly to the terminals of peripheral sensory 
neurons in the skin, allowing simple quantification of unilateral pain behaviors while avoiding 
systemic adverse effects. Intraplantar injection of the NaV1.7 activator OD1 (10–300 nM) led to the 
development of spontaneous pain behaviors in a concentration-dependent manner, as evidenced by 
licking, flinching, lifting and shaking of the injected hind paw, consistent with the spontaneous action 
potential firing seen in A- and C-fibers (Figure 3A). These spontaneous pain behaviors developed 
rapidly, occurring immediately after injection, and persisted for up to 40 min after injection of the 
highest concentration (300 nM). Intraplantar injection of phosphate-buffered saline/0.1% BSA alone 
caused no spontaneous pain behaviors. No significant changes in mechanical (paw withdrawal force: 
OD1 (300 nM), 2.5 ± 0.5 g; control, 2.9 ± 0.5 g; n = 4, p > 0.05) or thermal thresholds (time to withdrawal: 
OD1 (300 nM), 8.0 ± 2 s; control, 11.0 ± 1 s; n = 4, p > 0.05) were detected 45 min after injection of OD1 
(300 nM), the time by which spontaneous pain behaviors had resolved. As OD1 at a concentration of 
300 nM was found to elicit robust responses, this concentration was used for further behavioral studies. 
Since OD1 has activity at NaV1.6 at higher concentrations (EC50 = 30–47 nM) [15] and activation 
of NaV1.6 can also cause spontaneous pain behaviors [18], we next assessed the relative contribution 
of NaV1.7 and NaV1.6 to spontaneous pain behaviors induced by OD1 (Figure 3B). Co-administration of 
tetrodotoxin (TTX) with OD1 completely reversed spontaneous pain behaviors, confirming the 
involvement of only TTX-sensitive NaV subtypes (spontaneous pain behaviors/10 min: control, 105 ± 6; 
TTX (1 μM), 3 ± 2); p < 0.05). Co-administration with the NaV1.6 inhibitor GIIIA [19] reduced spontaneous 
pain behaviors by 33%, indicating partial involvement of NaV1.6 (spontaneous pain behaviors/10 min: 
control, 105 ± 6; GIIIA (10 μM), 71 ± 8); p < 0.05). In contrast, co-administration with the NaV1.7 
inhibitor GpTx-1 (see the full NaV selectivity in Table 1) completely reversed spontaneous pain 
behaviors, confirming a major role for NaV1.7 in mediating spontaneous pain behaviors induced by 
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Figure 2. Effects of NaV1.7 activation by O 1 on - and C-fibers using the mouse skin-saphenous
nerve preparation. (A) OD1 caused spontaneous firing of action potentials in 57% of the A-fibers tested
(action potentials/2 min: control, 0 ˘ 0; OD1 (30 nM), 13 ˘ 7; n = 7). (B) Action potentials plotted
as a function of instantaneous firing frequency from an A-fiber before and after perfusion of OD1.
Each point represents a single action potential, with the position on the y-axis indicating the frequency
relative to the preceding action potential. (C) OD1 caused spontaneous firing of action potentials
in 29% of the C-fibers tested (action potentials/2 min: control, 1 ˘ 0.6; OD1 (30 nM), 8 ˘ 5; n = 7).
(D) Action potentials plotted as a function of instantaneous firing frequency from a C-fiber before and
after perfusion of OD1. Each po nt repr sents a single acti n potential, with the position on the y-axis
indicating the frequency relative to the preceding action potential.
2.3. Intraplantar Injection of OD1 Causes Spo taneous Pain Behavior in Mice M diated Through NaV1.7
To assess the effect of OD1 on pain behaviors in mice, we chose the intraplantar route of
administration, as this route delivers the peptide directly to the terminals of peripheral sensory neurons
in the skin, allowing simple quantification of unilateral pain behaviors while avoiding systemic adverse
effects. I traplantar injection of the NaV1.7 activator OD1 (10–300 nM) led to the development of
spontan ous pa behav ors in a concentration-dependent man er, as evidenc d by licking, flinching,
lifting and shaking of the injected hind paw, consistent with the s ontaneous action potential firing
seen in A- and C-fibers (Figure 3A). These spontaneous pain behaviors developed rapidly, occurring
immediately after injection, and persisted for up to 40 min after injection of the highest concentration
(300 nM). Intraplantar injection of phosphate-buffered saline/0.1% BSA alone caused no spontaneous
pain behaviors. No significant changes in mechanical (paw withdrawal force: OD1 (300 nM),
2.5 ˘ 0.5 g; control, 2.9 ˘ 0.5 g; n = 4, p > 0.05) or thermal thresholds (time to withdrawal: OD1
(300 nM), 8.0 ˘ 2 s; control, 11.0 ˘ 1 s; n = 4, p > 0.05) were detected 45 min after injection of OD1
(300 nM), the time by which spontaneous pain behaviors had resolved. As OD1 at a c centration of
300 nM was found to elicit robust responses, t is concentration was used for further behavioral studies.
Since OD1 has activity at NaV1.6 at higher concentratio s (EC50 = 30–47 nM) [15] and ac ivation
of NaV1.6 can also cause spontaneous pain behaviors [18], we next assessed the relative contribution
of NaV1.7 and NaV1.6 to spontaneous pain behaviors induced by OD1 (Figure 3B). Co-administration
of tetrodotoxin (TTX) with OD1 completely reversed spontaneous pain behaviors, confirming the
involvement of only TTX-sensitive NaV subtypes (spontaneous pain behaviors/10 min: control,
105 ˘ 6; TTX (1 µM), 3 ˘ 2); p < 0.05). Co-administration with the NaV1.6 inhibitor GIIIA [19] reduced
spontaneous pain behaviors by 33%, indicating partial involvement of NaV1.6 (spontaneous pain
behaviors/10 min: control, 105˘ 6; GIIIA (10 µM), 71˘ 8); p < 0.05). In contrast, co-administration with
the NaV1.7 inhibitor GpTx-1 (see the full NaV selectivity in Table 1) completely reversed spontaneous
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pain behaviors, confirming a major role for NaV1.7 in mediating spontaneous pain behaviors induced
by OD1 (spontaneous pain behaviors/10 min: control, 105 ˘ 6; GpTx-1 (1 µM), 6 ˘ 5); p < 0.05). A
major contribution of NaV1.7 to OD1-induced pain was also confirmed using NaV1.7´{´ mice, which
displayed significantly reduced spontaneous pain behaviors compared to Cre and loxP littermate
controls (Figure 3C; spontaneous pain behaviors/10 min: control, 129 ˘ 8; NaV1.7´{´, 41 ˘ 11;
p < 0.05).
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TTX (1 μM) or the NaV1.7 inhibitor GpTx-1 (1 μM) completely reversed spontaneous pain behaviors, 
while the NaV1.6 inhibitor GIIIA (10 μM) only had a partial effect. (C) NaV1.7−/− mice displayed 
significantly reduced spontaneous pain behaviors compared to Cre and loxP littermate controls. 
Statistical significance was determined using the t-test or one-way ANOVA with Dunnett’s post-test; 
* p < 0.05 compared to the control. Data are presented as the mean ± SEM, n = 3–9 per group. 
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GpTx-1 was recently reported as a NaV1.7-selective inhibitor isolated from the venom of the 
tarantula Grammostola porteri (identical in sequence to GTx1-15 isolated from Grammostola rosea [20]); 
however, the mechanism of action of GpTx-1 and selectivity across all NaV subtypes has not been 
reported. Using a Fluorometric Imaging Plate Reader (FLIPR) membrane potential assay, GpTx-1 was 
found to inhibit NaV1.7 with 100-fold selectivity over NaV1.4, NaV1.5 and NaV1.8, consistent with the 
selectivity profile previously reported from electrophysiological studies [9,20]. The GpTx-1 rank 
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dependence of activation (Figure 4C,D; V50: control, −20.52 ± 0.4 mV; GpTx-1 (10 nM), −21.4 ± 0.5 mV); 
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Figure 3. Mouse model of NaV1.7-mediated pain based on intraplantar injection of OD1. (A) Intraplantar
injection of OD1 (10–300 nM) caused spontaneous pain behaviors, as evidenced by licking, flinching,
lifting and shaking of the injected hind paw. Intraplantar injection of phosphate-buffered saline/0.1%
BSA alone caused no spontaneous pain behaviors. (B) Intraplantar injection of TTX (1 µM) or the
NaV1.7 inhibitor GpTx-1 (1 µM) completely reversed spontaneous pain behaviors, while the NaV1.6
inhibitor GIIIA (10 µM) only had a partial effect. (C) NaV1.7´{´ mice displayed significantly reduced
spontaneous pain behaviors compared to Cre and loxP littermate controls. Statistical significance was
determined using the t-test or one-way ANOVA with Dunnett’s post-test; * p < 0.05 compared to the
control. Data are presented as the mean ˘ SEM, n = 3–9 per group.
Table 1. IC50 values (in µM) at hNaV1.1–1.8 obtained from the Fluorometric Imaging Plate Reader
(FLIPR) membrane potential assay.
NaV Subtype GpTx-1 PF-04856264 CNV1014802
1.1 6 ˘ 2 247 ˘ 27 22 ˘ 7
1.2 5 ˘ 2 20 ˘ 11 13 ˘ 6
1.3 22 ˘ 6 >300 23 ˘ 13
1.4 326 ˘ 70 >300 10 ˘ 5
1.5 140 ˘ 40 >300 84 ˘ 34
1.6 17 ˘ 9 309 ˘ 91 15 ˘ 1
1.7 0.58 ˘ 0.1 0.30 ˘ 0.07 32 ˘ 14
1.8 68 ˘ 32 >300 6 ˘ 0.2
2.4. GpTx-1 is a Selective NaV1.7 Inhibitor that Reverses OD1-Induced Pain Behaviors
GpTx-1 was recently reported as a NaV1.7-selective inhibitor isolated from the venom of the
tarantula Grammostola porteri (identical in sequence to GTx1-15 isolated from Grammostola rosea [20]);
however, the mechanism of action of GpTx-1 and selectivity across all NaV subtypes has not been
reported. Using a Fluorometric Imaging Plate Reader (FLIPR) membrane potential assay, GpTx-1 was
found to inhibit NaV1.7 with 100-fold selectivity over NaV1.4, NaV1.5 and NaV1.8, consistent with the
selectivity profile previously reported from electrophysiological studies [9,20]. The GpTx-1 rank order
of potency (pIC50 ˘ SEM) was hNaV1.7 (6.27 ˘ 0.1) > hNaV1.2 (5.63 ˘ 0.3) > hNaV1.1 (5.30 ˘ 0.1) >
hNaV1.6 (4.88 ˘ 0.2) > hNaV1.3 (4.69 ˘ 0.1) > hNaV1.8 (4.49 ˘ 0.5) > hNaV1.5 (3.89 ˘ 0.1) > hNaV1.4
(3.61 ˘ 0.2) (Figure 4A,B; see also Table 1 for IC50 values and Figure S1 for a sample trace).
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Figure 4. NaV selectivity and in vivo effects of the spider peptide GpTx-1. Activity of GpTx-1 was
assessed in HEK cells heterologously expressing NaV1.1–NaV1.8 using FLIPR membrane potential
assays. (A) GpTx-1 selectively inhibited NaV1.7, with the following pIC50’s ranked in order of potency
(hNaV1.7 (6.27 ˘ 0.1) > hNaV1.2 (5.63 ˘ 0.3) > hNa 1.1 (5.30 ˘ 0.1) > hNaV1.6 (4.88 ˘ 0.2) > hNaV1.3
(4.69 ˘ 0.1) > hNaV1.8 (4.49 ˘ 0.5) > hNaV1.5 (3.89 ˘ 0.1) > hNaV1.4 (3.61 ˘ 0.2). Data are presented
as the mean ˘ SEM from three independent experim nts. (B) Representative concentration response
curves of GpTx-1 at NaV1.1–NaV1.8. (C–F) Activity of GpTx-1 in CHO cells heterologously expressing
hNaV1.7 assessed by automated patch clamping. (C) Current-voltage (IV) relationship before and
after the addition GpTx-1. (D) Voltage dependence of activation and fast inactivation before and after
the addition of GpTx-1. GpTx-1 (10 nM) had no significant effect on the voltage of activation (V50:
control, ´20.52 ˘ 0.4 mV; GpTx-1 (10 nM), ´21.4 ˘ 0.5 mV), but shifted the voltage dependence of
fast inactivation to more hyperpolarized potentials (V50: control, ´58.66 ˘ 0.3 mV; GpTx-1 (10 nM),
´64.58 ˘ 0.5 mV). (E) Trace of sodium currents before (black) and after addition of 1 µM GpTx-1
(red). GpTx-1 causes full inhibition of the peak current that was partially reversed (highlighted by the
points) by a strong depolarization pulse (+200 mV for 50 ms). (F) Concentration response curve of
GpTx-1 elicited by a 20-ms pulse to 0 mV from a holding potential of ´100 mV or an 8-s conditioning
voltage step of ´55 mV with and without OD1 (300 nM). GpTx-1 had no significant preference for the
open/inactivated state (IC50 8 nM) compared to the closed/resting state (IC50 13 nM). The presence of
OD1 (300 nM) did not significantly affect the potency of GpTx-1 in the open/inactivated state (IC50
3 nM) or in the closed/resting state (IC50 8 nM). Data are presented as the mean ˘ SEM, n = 10–14.
(G) Intraplantar administration of GpTx-1 (30 nM, 100 nM, 300 nM, 1 µM) concentration-dependently
reversed spontaneous pain behaviors in mice evoked by OD1. (H) Intraperitoneal administration of
GpTx-1 (0.1 mg/kg) had no significant (n.s.; p > 0.05) effect on spontaneous pain behaviors in mice
induced by OD1. Statistical significance was determined using the t-test or one-way ANOVA with
Dunnett’s post-test; * p < 0.05 compared to the vehicle control. Data are presented as the mean ˘ SEM,
n = 3–9 per group.
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GpTx-1 inhibited the peak current of hNaV1.7 without significantly shifting the voltage
dependence of activation (Figure 4C,D; V50: control, ´20.52 ˘ 0.4 mV; GpTx-1 (10 nM),
´21.4 ˘ 0.5 mV); however, a shift in the voltage dependence of fast inactivation to more hyperpolarized
potentials was observed (Figure 4D; V50 for control ´58.66 ˘ 0.3 mV and GpTx-1 (10 nM)
´64.58 ˘ 0.5 mV). GpTx-1 caused full inhibition of peak current at 1 µM, which was partially reversed
after a strong depolarizing pulse to +200 mV for 50 ms (Figure 4E), an effect often seen with gating
modifier toxins [21]. GpTx-1 displayed minimal state dependence, with an IC50 of 8 nM in the
open/inactivated state and 13 nM in the closed/resting state (Figure 4F). The potency of GpTx-1 was
not significantly affected by the presence of OD1 (300 nM) in the open/inactivated state (IC50 3 nM) or
in the closed/resting state (IC50 8 nM) (see Figure S2 for a sample trace).
Intraplantar injection of GpTx-1 co-administered with OD1 potently and concentration-dependently
reduced spontaneous pain behaviors, causing almost complete reversal at the highest concentration
(Figure 4G; spontaneous pain behaviors/10 min: control, 105 ˘ 6; GpTx-1 (1 µM), 6 ˘ 5; GpTx-1
(300 nM), 17 ˘ 4; GpTx-1 (100 nM), 34 ˘ 2; GpTx-1 (30 nM), 68 ˘ 9; p < 0.05). However, intraperitoneal
injection of GpTx-1 at the highest tolerated dose (0.1 mg/kg) had no significant effect on spontaneous
pain behaviors (Figure 4H). At a dose of 0.3 mg/kg, GpTx-1 causes motor deficits, as evidenced by a
significant increase in the ataxia index (Figure 5A; ataxia index: control, 2.7 ˘ 0.4; GpTx-1 (0.3 mg/kg),
9.7 ˘ 3.4; p < 0.05). Therefore, it was not possible to assess the effect of GpTx-1 at systemic doses above
0.1 mg/kg.
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Figure 5. Motor assessment of systemically (i.p.) delivered GpTx-1, PF-04856264 and CNV1014802.
(A) Ataxia index (number of foot sl ps per met rs tr velled) assess d by the Parallel Rod Floor Test.
GpTx-1 (0.3 mg/kg; n = 4) significantly increased the ataxia index, while PF-04856264 (30 mg/kg;
n = 5) and CNV1014802 (30 mg/kg; n = 3) had no significant effect compared to the vehicle control
(n = 12). (B) Distance travelled (m) assessed by the Parallel Rod Floor Test. CNV1014802 (30 mg/kg;
n = 3) significantly reduc d the istance travelled, while GpTx-1 (0.3 mg/kg; n = 4) and PF-04856264
(30 mg/kg; n = 5) had no significa t effect compared to the vehicle control (n = 12). Statistical
significance was determined using one-way ANOVA with Dunnett’s post-test; * p < 0.05 compared to
the vehicle control. Data are presented as the mean ˘ SEM.
2.5. PF-04856264 Is a Selective NaV1.7 Inhibitor that Reverses OD1-Induced Pain Behaviors
PF-04856264 is a novel aryl sulfonamide NaV1.7 inhibitor with little effect on NaV1.3 and NaV1.5,
although activity at the other NaV subtypes has not been reported [17]. Using the FLIPR membrane
potential assay, we found that PF-04856264 was a selective NaV1.7 inhibitor with >40-fold selectivity
over all other NaV subtypes and >1000-fold selective over NaV1.4–NaV1.6. The rank order of potency
(pIC50 ˘ SEM) was hNaV1.7 (6.53 ˘ 0.1) > hNaV1.2 (4.87 ˘ 0.3) > hNaV1.1 (3.61 ˘ 0.1) > hNaV1.6
(3.53 ˘ 0.1) >> hNaV1.3 ~ h aV1.4 ~ hNaV1.5 ~ hNaV1.8 (Figure 6A,B; see also Table 1 for IC50 values
and Figure S1 for a sample trace). Interestingly, PF-04856264 only partially inhibited responses in the
FLIPR assay, leaving a residual 25%–30% change in membrane potential unaffected, despite completely
inhibiting NaV1.7 current in patch clamp assays (see below). PF-04856264 acts as a gating modifier,
interacting with the voltage sensor in Domain IV and preferentially binding to and stabilizing the
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inactivated state of NaV1.7 [17]. We confirmed the state dependence of PF-04856264 inhibition, finding
a 20-fold shift in the NaV1.7 IC50 from closed/resting state inhibition (2.7 µM) to open/inactivated
state inhibition (134 nM) (Figure 6C). Interestingly, in the presence of OD1 (300 nM), PF-04856264 had
a three-fold loss of potency in both the closed/resting state (IC50 11 µM) and the open/inactivated
state (IC50 445 nM) (see Figure S2 for a sample trace).
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Figure 6. NaV selectivity and in vivo effects of the aryl sulfonamide PF-04856264. Activity of
PF-04856264 was assessed in HEK cells heterologously expressing NaV1.1–NaV1.8 using FLIPR
membrane potential assays. (A) PF-04856264 selectively inhibited NaV1.7, with the following pIC50’s
ranked in order of potency: hNaV1.7 (6.53˘ 0.1) > hNaV1.2 (4.87˘ 0.3) > hNaV1.1 (3.61˘ 0.1) > hNaV1.6
(3.53 ˘ 0.1). PF-04856264 had o inh bitory activity at the other NaV subtypes up to a concentration of
300 µM. Data are presented as the mean˘ SEM from three independent experiments. (B) Representative
concentration response curves of PF-04856264 at NaV1.1, 1.2, 1.6 and 1.7. (C) Activity of PF-04856264 in
CHO cells heterologously expressing hNaV1.7 ass ss d by au om d patch clamping. Concentration
response curve of PF-04856264 elicited by a 20-ms pulse to 0 mV from a holding potential of´100 mV or
an 8 s conditioning voltage step of ´55 mV with and without OD1 (300 nM). PF-04856264 preferentially
bound to the open/inactivated state (IC50 134 nM) compared t he closed/resting state (IC50 2.7 µM).
The presence of OD1 (300 nM) reduced the potency of PF-04856264 in both the open/inactive state
(IC50 445 nM) and the closed/resting state (IC50 11 µM). Data are presented as the mean˘ SEM, n = 6–14.
(D) Intraplantar administration of PF-04856264 (10 µM, 100 µM, 1 mM) concentration-dependently
reversed spontaneous pain behaviors in mice evoked by OD1. (E) Intraperitoneal administration of
PF-04856264 (30 mg/kg) also significantly reduced spontaneous pain behaviors in mice. Statistical
significance was determined using one-way ANOVA with Dunnett’s post-test; * p < 0.05 compared to
the vehicle control. Data are presented as the mean ˘ SEM, n = 3–9 per group.
Intraplantar injection of PF-04856264 concentration-dependently reduced spontaneous pain
behaviors induced by co-administered OD1 (300 nM), although surprisingly, the high local
concentrations required did not correlate with its in vitro potency (Figure 6D; spontaneous pain
behaviors/10 min: control, 105 ˘ 6; PF-04856264 (1 mM), 19 ˘ 6; PF-04856264 (100 µM), 31 ˘ 8;
PF-04856264 (10 µM), 81 ˘ 12; p < 0.05). Intraperitoneal administration of PF-04856264 was also
effective (Figure 6E; spontaneous pain behaviors/10 min: control, 105 ˘ 6; PF-04856264 (30 mg/kg),
42 ˘ 8; p < 0.05) and well tolerated, with no significant motor adverse effects observed at doses up to
30 mg/kg, correlating well with the in vitro selectivity profile (Figure 5A; ataxia index: control, 2.7 ˘ 0.4;
PF-04856264 (30 mg/kg), 4.6 ˘ 1.3; p > 0.05; Figure 5B; distance travelled: control, 1.49 ˘ 0.16 m;
PF-04856264 (30 mg/kg), 1.03 ˘ 0.17 m; p > 0.05).
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2.6. CNV1014802 is a Non-Selective NaV Inhibitor
CNV1014802 is reported to be a state-dependent inhibitor of NaV1.7; however, information on
the potency and selectivity profile has not been reported [8]. Surprisingly, CNV1014802 was found
to be a relatively non-selective NaV inhibitor, in the FLIPR membrane potential assay, with a rank
order of potency (pIC50 ˘ SEM): hNaV1.8 (5.25 ˘ 0.1) > hNaV1.4 (5.09 ˘ 0.2) > hNaV1.2 (4.99 ˘ 0.2) >
hNaV1.6 (4.84 ˘ 0.1) > hNaV1.3 (4.82 ˘ 0.3) > hNaV1.1 (4.70 ˘ 0.2) > hNaV1.7 (4.58 ˘ 0.2) > hNaV1.5
(4.18 ˘ 0.2) (Figure 7A,B; see also Table 1 for IC50 values and Figure S1 for a sample trace). We
were able to confirm the state-dependence reported for CNV1014802, finding a nine-fold shift in the
NaV1.7 IC50 between closed/resting state inhibition (54 µM) and open/inactivated state inhibition
(6.3 µM), with a preference for the open/inactivated state (Figure 7C). Compared to PF-04856264, the
potency of CNV1014802 at NaV1.7 is 50-fold weaker; however, the presence of OD1 (300 nM) did not
significantly affect the potency of CNV1014802 at Nav1.7 in the closed/resting state (IC50 35 µM) or
the open/inactivated state (IC50 11 µM) (see Figure S2 for a sample trace).
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Figure 7. NaV selectivity and in vivo effects of the clinical candidate CNV1014802. Activity of
CNV1014802 was assessed in HEK cells heterol gously expressing NaV1.1–NaV1.8 using FLIPR
membrane potential assays. (A) CNV1014802 non-selectively inhibited NaV channels, with the
following pIC50’s ranked in order of potency: hNaV1.8 (5.25 ˘ 0.1) > hNaV1.4 (5.09 ˘ 0.2) > hNaV1.2
(4.99 ˘ 0.2) > hNaV1.6 (4.84 ˘ 0.1) > hNaV1.3 (4.82 ˘ 0.3) > hNaV1.1 (4.70 ˘ 0.2) > hNaV1.7 (4.58 ˘ 0.2)
> hNaV1.5 (4.18 ˘ 0.2). Data are presented as the mean ˘ SEM from three independent experiments.
(B) Representative concentration response curves of CNV1014802 at NaV1.1–1.8. (C) Activity of
CNV1014802 in CHO cells heterologously expressing hNaV1.7 assessed by automated patch clamping.
Concentration response curve of CNV1014802 elicited by a 20-ms pulse to 0 mV from a holding potential
of ´100 mV or an 8-s condition voltage step of ´55 mV with and without OD1 (300 nM). CNV1014802
preferentially bound to the open/inactivated state (IC50 6.3 µM) compared to the closed/resting state
(IC50 54 µM). The presence of OD1 (300 nM) did not significantly affect the potency of CNV1014802.
Data are presented as the mean ˘ SEM, n = 4–7. (D) Intraplantar administration of CNV1014802
(1 mM) had no significant effect on spontaneous pain behaviors in mice evoked by OD1. (E) However,
intraperitoneal administration of CNV1014802 (3 and 30 mg/kg) significantly reduced spontaneous
pain behaviors in mice. Statistical significance was determined using the t-test or one-way ANOVA with
Dunnett’s post-test; * p < 0.05 compared to the vehicle control. Data are presented as the mean ˘ SEM,
n = 3–9 per group.
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Despite in vitro activity at hNaV1.7, CNV1014802 was unable to significantly attenuate
OD1-induced spontaneous pain behaviors when delivered locally by intraplantar injection at a
concentration of 1 mM (Figure 7D). However, CNV1014802 was effective when delivered by the
intraperitoneal route (Figure 7E; spontaneous pain behaviors/10 min: control, 105 ˘ 6; CNV1014802
(30 mg/kg), 45 ˘ 5; CNV1014802 (3 mg/kg), 60 ˘ 8; p < 0.05), with sedative adverse effects observed
at the highest dose, as evidenced by a significant reduction in distance travelled, but no significant
increase in the ataxia index (Figure 5A; ataxia index: control, 2.7 ˘ 0.4; CNV1014802 (30 mg/kg),
3.5 ˘ 1.9; p > 0.05; Figure 5B; distance travelled: control, 1.49 ˘ 0.16 m; CNV1014802 (30 mg/kg),
0.66 ˘ 0.20 m; p < 0.05).
3. Discussion
Choosing a relevant animal pain model to evaluate the analgesic efficacy of NaV1.7-selective
inhibitors is an essential step in the pre-clinical development of these compounds. We therefore
developed a novel mouse model of NaV1.7-mediated pain based on intraplantar injection of
the scorpion toxin OD1 that allows rapid in vivo characterization of the analgesic efficacy of
NaV1.7 inhibitors.
OD1 was initially classed as a α-scorpion toxin that increases peak current by delaying fast
inactivation, but has little effect on the voltage dependence of activation at NaV1.7 expressed in oocytes
at 50 nM. [14,22]. Similarly, a small, albeit statistically-significant shift in the voltage dependence of
activation was recently reported at NaV1.7 expressed in mammalian cells [23]. Our results confirm
that this shift in the voltage dependence of activation is further enhanced at higher concentrations.
Thus, OD1 has mixed α/β-scorpion toxin effects at NaV1.7, not only increasing peak current and
delaying inactivation, but also shifting the voltage dependence of activation to more hyperpolarized
potentials. Thus, the mixed functional activity of OD1, which was also previously reported for NaV1.4
and NaV1.6 [15], appears to be concentration dependent, suggesting that OD1 preferentially interacts
with the α-scorpion toxin-binding site with additional interaction with the β-scorpion toxin-binding
site at higher concentrations. Both pharmacological effects are consistent with the ability of OD1
to induce spontaneous action potential firing in sensory neurons. While pure α-toxins would be
expected to amplify supra-threshold responses due to the inhibition of channel inactivation and would
lead to amplification of small generator potentials, a shift in the voltage dependence of activation
would additionally result in channel opening closer to resting membrane potential, resulting in greater
amplification of sub-threshold responses and induction of spontaneous action potential firing.
The functional effects of OD1 on NaV1.7 can be correlated to the functional consequences
of NaV1.7 gain-of-function mutations in the painful syndromes inherited erythromelalgia and
paroxysmal extreme pain disorder. Typically, mutations present in inherited erythromelalgia patients
cause a voltage-dependent shift of activation of NaV1.7 to more hyperpolarized potentials [24–27],
corresponding to the β-scorpion toxin-like effects of OD1, whereas paroxysmal extreme pain disorder
mutations generally delay the fast inactivation [28–30], corresponding to the α-scorpion toxin activity
of OD1. This indicates that the OD1 mouse model may be used to identify new analgesics with the
potential to treat the poorly managed conditions of inherited erythromelalgia and paroxysmal extreme
pain disorder.
NaV1.7 is preferentially expressed in the majority of peripheral sensory neurons that have been
functionally characterized as nociceptive A- and C-fibers [31]. Specifically, it is present on the peripheral
terminals of nociceptive neurons, where it contributes to the amplification of sub-threshold generator
potentials by producing ramp currents that depolarize the membrane to the threshold required to
generate an action potential [32,33]. Application of OD1 to the receptive fields of A- and C-fibers caused
spontaneous action potential firing, consistent with the effect of OD1 on the biophysical properties
of NaV1.7, which would result in depolarization closer to resting membrane potential, leading to
spontaneous action potential firing. The spontaneous pain behaviors induced by intraplantar injection
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of OD1 are consistent with the spontaneous action potential firing seen in A- and C-fibers in the
skin-nerve preparation.
Although OD1 is a selective NaV1.7 activator, it also has activity at NaV1.6, albeit at higher
concentrations. Given that intraplantar administration of the NaV1.6 activator Cn2 also causes
spontaneous pain behaviors in mice [18], we assessed the relative contribution of NaV1.7 and NaV1.6
to spontaneous pain behaviors induced by OD1. While the NaV1.6 inhibitor GIIIA partially reversed
OD1-induced spontaneous pain by 33%, the NaV1.7 selective inhibitors GpTx-1 and PF-04856264
were effective after intraplantar injection at concentrations unlikely to significantly inhibit NaV1.6
in vivo, suggesting that the majority of spontaneous pain behaviors induced by OD1 are mediated
through NaV1.7. This was further confirmed in NaV1.7´{´ mice, where the behavioral phenotype
was strongly attenuated, with residual responses likely attributable to the NaV1.6 activity of OD1.
Thus, OD1 elicited a robust and long-lasting behavioral response that was mediated predominantly
through NaV1.7, allowing the efficacy of NaV1.7 inhibitors to be readily assessed for their potential in
the treatment of NaV1.7-mediated pain.
Consistent with its reported activity at NaV1.7 [20], GpTx-1 was found to significantly reduce
OD1-induced spontaneous pain behaviors when administered locally. The reasons for the potent
in vivo effects of GpTx-1 are not entirely clear. Peptide NaV inhibitors can have particularly slow
off-rates, which could contribute to high apparent in vivo potency. In addition, it is currently unclear
what level of NaV1.7 inhibition is required to cause analgesia, although it is reasonable to assume that
complete inhibition of NaV1.7 current may not be required to prevent NaV1.7-mediated action potential
firing. Thus, for compounds that are able to achieve relevant free drug concentrations at peripheral
nerve endings and that can achieve full inhibition of current at relevant states, the in vivo IC50 may
be lower than the observed in vitro IC50. Although effective locally, we were not able to reproduce
this effect with systemic delivery of GpTx-1. This is likely due to dose-limiting side effects, as the
maximum tolerated systemic dose (0.1 mg/kg) may not have achieved sufficiently high concentration
at peripheral nerve endings in the hind paw to inhibit NaV1.7. Motor adverse effects were observed at
doses above 0.1 mg/kg, limiting administration of higher doses, and were most likely attributable to
activity at NaV1.6, which is expressed in the periphery on sensory and motor neurons, where loss of
function leads to movement disorders and hind limb paralysis [34]. This suggests that greater than
the 30-fold selectivity for NaV1.7 over NaV1.6 seen with GpTx-1 is required to have an acceptable
therapeutic window for systemic use; however, off-target activity at other NaV isoforms may also
contribute to the adverse effects.
In contrast, the aryl sulfonamide PF-04856264 displayed excellent selectivity (>1000 fold) for
NaV1.7 over NaV1.4–NaV1.6. This selectivity profile was reflected in vivo, with relatively high systemic
doses (30 mg/kg) causing no significant motor adverse effects. PF-04856264 was effective at reversing
OD1-induced spontaneous pain behaviors when delivered both locally and systemically, although
higher than expected doses were required to elicit analgesia by either routes relative to its potency in
the FLIPR membrane potential (IC50 300 nM) and electrophysiology (IC50 130 nM) assays. However,
given that PF-04856264 preferentially binds to NaV1.7 in the inactivated state, it is possible that
the delayed inactivation produced by OD1 promoted an unfavorable channel state for PF-04856264
binding. Indeed, the presence of OD1 led to a three-fold loss of potency in the electrophysiological
assays. State-dependent inhibition of NaV1.7 may also explain the inability of PF-04856264 to fully
block membrane potential changes using the fluorescence assay, where residual responses could be
mediated by veratridine-modified channels resistant to inactivation that in turn are unaffected by
PF-04856264 [35]. The physiological relevance of a preference for the inactivated state of NaV1.7 in
other pathological pain conditions remains to be established, although such a mechanism might imply
lack of efficacy in paroxysmal extreme pain disorder, where NaV1.7 channels are relatively resistant to
fast inactivation.
Consistent with previous reports, CNV1014802 also was a state-dependent inhibitor of NaV1.7 in
our hands, although it lacked the NaV subtype selectivity of PF-04856264. Surprisingly, CNV1014802
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lacked in vivo analgesic efficacy when delivered locally at a concentration of 1 mM, perhaps
reflecting its relatively poor potency at NaV1.7 in membrane potential (32 µM) and electrophysiology
(6.3 µM) assays. In addition, CNV1014802 (formally GSK1014802 and now raxatrigine) is reported
to be highly (94%) protein bound, which could also lead to a decrease in free effective drug at the
site of action after local administration [36]. In contrast to local administration, CNV1014802 was
effective when administered systemically, although some sedative adverse effects were observed at
the highest dose (30 mg/kg). These effects are consistent with the reported ability of CNV1014802
to penetrate the central nervous system, which likely is crucial for its efficacy in animal models of
seizures and schizophrenia [36,37], suggesting that analgesic activity after systemic dosing may also
be due to central effects.
Based on our pharmacological validation, the OD1-induced spontaneous pain model can be used
to assess the in vivo activity of compounds when delivered by both the intraplantar and a systemic
route. An advantage of the intraplantar route is that it uses considerably less material and thus may be
the preferable route of administration for screening compounds for in vivo activity in the early stages
of lead identification. However, as was the case for PF-04856264 and CNV1014802, in vivo activity
in the OD1 model did not correspond well with the in vitro potency found in the electrophysiology
and FLIPR membrane potential assays. At least in the case of PF-04856264, species-specific effects
are unlikely to contribute to this discrepancy, as equipotency at human and mouse NaV1.7 has
been previously reported [17]. In addition, although PF-04856264 lost potency in the presence of
OD1, consistent with preferential binding to the inactivated state, this change was relatively small
and would not explain the relative lack of potency in vivo. Interestingly, we observed incomplete
inhibition of NaV1.7-mediated responses in the FLIPR membrane potential assay by PF-04856264
and CNV1014802 (Figure S1), although both compounds completely inhibited currents from NaV1.7
patch-clamp recordings. While it is unclear whether this effect correlates to the ability of these
compounds to prevent activity-induced membrane depolarization at peripheral sensory nerve endings
in vivo, such effects may contribute to the poor in vivo activity observed. In addition, it is plausible
that other factors, such as the pharmacokinetic properties of these compounds, affect in vivo efficacy.
Nonetheless, these results highlight the need for a simple animal model, such as the OD1 model
described here, which permits rapid evaluation of in vivo on-target effects, as the in vitro properties do
not always correspond well to in vivo activity.
Scorpion α-toxins, such as OD1, are known to bind to Domain IV [38]; however, we have
demonstrated that efficacy in the OD1 model is not dependent on competitive binding at this site. For
example, TTX, which binds to the pore of the channel, and GpTx-1, which binds to Domain II [39], were
both able to completely abolish OD1-induced spontaneous pain behaviors. Although not as potent
in vivo, the state-dependent inhibitors PF-04856264, predicted to share an overlapping binding site
with scorpion α-toxins on Domain IV [17], and CNV1014802 (binding site remains to be determined)
were also effective. Thus, the OD1 model is suitable to evaluate in vivo activity of NaV1.7 inhibitors
irrespective of their mechanism of action or binding site.
In conclusion, we have established a NaV1.7-mediated mouse model of pain based on intraplantar
injection of the scorpion toxin OD1 and pharmacologically characterized the activity of the spider
peptide GpTx-1, the small molecule PF-04856264 and the clinical candidate CNV1014802. The model is
suitable to evaluate in vivo on-target activity of NaV1.7 inhibitors; however, it is unclear if activity in
OD1-induced pain translates to anti-nociceptive or anti-allodynic effects in other rodent models or
analgesia in humans. While efficacy in the OD1 model is useful to validate in vivo on-target activity
at NaV1.7, species differences need to be considered carefully when using animal models of human
disease. Given the relatively high homology between mouse and human NaV isoforms, significant
pharmacological differences have rarely been reported. Indeed, PF-04856264 is equipotent at mouse
and human NaV1.7 [17], and the effects of OD1 on rodent NaV1.7 closely match the effects on human
NaV1.7 [15]. While NaV1.7 is arguably a well-validated pain target in humans based on genetic
evidence from loss-of-function and gain-of-function conditions, including congenital insensitivity
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to pain, erythromelalgia and paroxysmal extreme pain disorder, it remains to be established if
pharmacological inhibition of NaV1.7 can achieve global graded analgesia.
4. Experimental Section
4.1. Chemicals
OD1 was synthesized as previously described [15]. PF-04856264 was from SYNthesis Med Chem
(Parkville, VIC, Australia) and CNV1014802 was from Axon MedChem (Groningon, The Netherlands).
GIIIA was synthesized by Boc chemistry using methods previously described [40]. TTX was from
Tocris Bioscience (Bristol, UK), and veratridine was from Alomone Labs (Jerusalem, Israel). All other
reagents were from Sigma Aldrich (Castle Hill, NSW, Australia), unless otherwise stated. Peptides
were routinely diluted in 0.1% bovine serum albumin (BSA).
4.2. Synthesis of GpTx-1
Solvents for reversed-phase high-performance liquid chromatography (HPLC) consisted of 0.05%
trifluoroacetic acid (TFA)/H2O (A) and 90% acetonitrile/0.043% TFA/H2O (B). Analytical HPLC was
performed on a Shimadzu LC20AT system (Shimadzu, Kyoto, Japan) using a Thermo Hypersil GOLD
2.1 ˆ 100 mm C18 column (ThermoScientific, Brendale, QLD, Australia) heated at 40 ˝C with flow rate
of 0.3 mL/min. A gradient of 10–55% B over 30 min was used, with detection at 214 nm. Preparative
HPLC was performed on a Vydac 218TP1022 column (Grace, Columbia, MD, USA) running at a flow
rate of 16 mL/min using a gradient of 5%–45% B over 40 min. Mass spectrometry was performed on
an API2000 (ABI Sciex, Mt Waverley, VIC, Australia) mass spectrometer in positive ion mode.
Protected 9-fluorenylmethyloxycarbonyl (Fmoc) amino acid derivatives and
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were purchased
from Iris Biotech (Marktredwitz, Germany); Rink-amide resin, N,N-dimethylformamide (DMF),
N,N-diisopropylethylamine (DIEA) and TFA from Auspep (Tullamarine, VIC, Australia). All other
reagents were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia).
GpTx-1 was assembled on a Symphony (Protein Technologies Inc., Tucson, AZ, USA) automated
peptide synthesizer on a Rink-amide (loading 0.67 mmol/g) polystyrene resin on a 0.1 mmol scale.
Fmoc deprotections were achieved using 30% piperidine/DMF (1ˆ 1.5 min, then 1ˆ 4 min). Couplings
were performed in DMF using 5 equivalents of Fmoc-amino acid/HBTU/DIEA (1:1:1) relative to resin
loading for 2 ˆ 20 min. Amino acid side-chains were protected as Asn(Trt), Asp(OtBu), Arg(Pbf),
Cys(Trt), His(Trt), Lys(Boc), Ser(tBu), Thr(tBu), Trp(Boc), Tyr(tBu). Cleavage from the resin and removal
of side-chain protecting groups was achieved by treatment with 95% TFA/2.5% TIPS/2.5% H2O at
room temperature for 2 h. After most of the cleavage solution was evaporated under a stream of N2,
the product was precipitated and washed with cold Et2O and lyophilized from 50% acetonitrile/0.1%
TFA/H2O 223 mg; ESI-MS (m/z): calc. (average) 1021.0 [M + 4H]4+, found 1020.8.
Purified reduced peptide (41 mg), reduced glutathione (100 equiv) and oxidized glutathione (10
equiv.) were dissolved in 6 M GnHCl (21 mL) then added to a solution of 0.36 M NH4OAc (pH 8.0,
230 mL) and stirred at room temperature with exposure to air for 48 h. The single major product was
isolated by preparative HPLC: 13.5 mg; ESI-MS (m/z): calc. (average) 1019.5 [M + 4H]4+, found 1019.4.
The crude product was purified by preparative HPLC to give 42 mg of hexathiol GpTx-1 (99% purity).
4.3. Animals
Ethical approval for in vivo experiments in animals was obtained from The University of
Queensland animal ethics committee (PHARM/261/13/ARC and IMB/PACE/326/15). Experiments
involving animals were conducted in accordance with the Animal Care and Protection Regulation
Qld (2012), the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes,
8th edition (2013, and the International Association for the Study of Pain Guidelines for the Use of
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Animals in Research. All efforts were made to minimize animal suffering and to reduce the number of
animals used.
For behavioral assessment, we used adult male C57BL/6J mice aged 6–8 weeks. Animals were
housed in groups of 3 or 4 per cage, under 12-h light-dark cycles and had standard rodent chow and
water ad libitum. Advillin-Cre constitutive NaV1.7 knockout mice were kindly provided by Professor
John N. Wood (University College London) [41].
4.4. Behavioral Assessment Following Injection of OD1
OD1 was diluted in phosphate-buffered saline/0.1% BSA (10–300 nM) and administered by
shallow subcutaneous (intraplantar) injection to the left hind paw of mice in a volume of 40 µL
under light isoflurane (3%) anesthesia. Mice were then placed individually into polyvinyl boxes
(10 ˆ 10 ˆ 10 cm), and spontaneous pain behavior (licks and flinches) was counted by an investigator
unaware of the treatments received from video recordings for 40 min post-injection at 5-min intervals.
Once spontaneous pain behavior had ceased, mechanical and thermal allodynia was assessed using
an electronic von Frey apparatus (MouseMet Electronic von Frey, TopCat Metrology, Ely, UK) and
the Hargreaves method (Plantar Analgesia Meter, IITC, Woodland Hills, CA, USA), as previously
described [42].
4.5. Effect of Pharmacological Inhibitors and Clinical Compounds
OD1 (300 nM) was administered as described above, and cumulative spontaneous pain behaviors
were quantified for 10 min immediately post-injection of OD1 by a blinded observer. Compounds
delivered by the intraplantar route were co-injected with OD1 at the concentrations stated. Compounds
delivered by the intraperitoneal route were administered 15 min prior to injection of OD1 at the doses
stated in a volume of 10 µL/g. All compounds were diluted in phosphate-buffered saline, except
PF-04856264 and CNV1014802, which were diluted in phosphate-buffered saline/10% DMSO due to
poor solubility.
4.6. Motor Performance Assessment
Motor performance was assessed using the Parallel Rod Floor Test and analyzed using ANY-Maze
software (Stoelting Co., version 4.70, Wood Dale, IL, USA). GpTx-1 (0.3 mg/kg), PF-04856264
(30 mg/kg) and CNV1014802 (30 mg/kg) were administered by the intraperitoneal route, as described
above, 15 min prior to assessment of motor performance. Mice were then placed in the Parallel Rod
Floor Test apparatus, and the distance travelled (m) and number of foot slips were recorded over 1
min using the ANY-Maze software. The ataxia index was calculated by dividing the number of foot
slips by the distance travelled (m).
4.7. Skin-Nerve Preparation
The effect of OD1 on A- and C-fibers was assessed using single fiber recordings from isolated
mouse skin-saphenous nerve preparations, as previously described [43]. Briefly, the saphenous nerve
along with the skin of the dorsal hind paw and lower leg of adult C57BL/6J mice was removed
and placed in an organ chamber, perfused with carbogenated synthetic interstitial fluid containing
the following (in mM): NaCl (107.8), KCl (3.5), MgSO4 (0.69), NaHCO3 (26.2), NaH2PO4 (1.67),
Na-gluconate (9.64), glucose (5.55), sucrose (7.6) and CaCl2 (1.53); pH 7.3. The saphenous nerve
was placed in a separate recording chamber immersed in paraffin oil and was desheathed and teased
apart until a single fiber recording was identified by mechanically probing the corresponding receptive
field. Fibers were then classified based on conduction velocity assessed by electrical stimulation of the
receptive field with a microelectrode (C-fiber < 1 m/s, A-fiber 1.6–12 m/s). The receptive field was
isolated using a plastic ring, and OD1 (30 nM) was continuously perfused at a rate of 8 mL/min at
32 ˝C. Data were recorded and analyzed using DAPSYS, Version 8.
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4.8. Cell Culture
Human embryonic kidney (HEK 293) cells stably expressing hNaV1.1, hNaV1.2, hNaV1.3, hNaV1.4,
hNaV1.5, hNaV1.7 and hNaV1.8 (SB Drug Discovery, Glasgow, UK) were cultured in MEM containing
10% v/v fetal bovine serum supplemented with L-glutamine (2 mM) and selection antibiotics as
recommended by the manufacturer. HEK 293 cells stably expressing hNaV1.6 (kind gift from Dr. Frank
Lehmann-Horn, University of Ulm, Germany) were cultured in DMEM containing 10% v/v fetal bovine
serum and geneticin 0.5 mg/mL. CHO cells stably expressing hNav1.7 (Chantest, OH, USA) were
cultured in Ham’s F12 containing 10% v/v fetal bovine serum and selection antibiotics, as recommended
by the manufacturer. Cells were grown in a humidified 5% CO2 incubator at 37 ˝C, grown to 70%–80%
confluence and passaged every 3–4 days using TrypLE Express (Invitrogen, Scoresby, VIC, Australia).
4.9. FLIPR Membrane Potential Assays
HEK 293 cells stably expressing hNaV1.1–1.8 were plated 48 h before the assay on 384-well
black-walled imaging plates at a density of 10,000–15,000 cells per well and were loaded with red
membrane potential dye (Molecular Devices, San Francisco, CA, USA) according to the manufacturer’s
instructions for 30 min at 37 ˝C. After the addition of GpTx-1, PF-04856264 and CNV1014802 using the
FLIPRTETRA, cells were incubated a further 5 min before stimulating NaV using veratridine (60 µM,
NaV1.1–NaV1.7) or deltamethrin (150 µM, NaV1.8). Changes in membrane potential were assessed
using the FLIPRTETRA (excitation 515–545 nm, emission 565–625 nm) every second for 300 s after
adding agonists. To quantitate the effect of test compounds on NaV responses, the area under the
curve (AUC) corresponding to 300 s after the addition of veratridine was computed using ScreenWorks
(Molecular Devices, Version 3.2.0.14) and normalized to buffer responses (0%) and veratridine control
responses (100%).
4.10. Electrophysiology
CHO cells were used for the electrophysiology, because in our experience, they are more robust
to clamp compared to HEK cells. CHO hNaV1.7 were passaged 48 h prior to the assay in a T-175
flask and cultured in selection-free media at 37 ˝C or CHO hNav1.7 EZCells™ were thawed the day
of the experiment according to the manufacture’s specifications. To induce expression in the CHO
hNaV1.7 cells, tetracycline (1 µg/mL) was added to culture media 24 h prior to the assay. Cells were
harvested at 70%–80% confluence and resuspended to 1 ˆ 106 cells/mL in Ex-Cell ACF CHO Medium
with 25 mM HEPES and 1ˆ Glutamax (Gibco, Thermo Fisher Scientic, Scoresby, VIC, Australia) before
being transferred to the QPatch QStirrer and allowed to recover for 30 min. Extracellular solution
(EC) was used to resuspend all test compounds and contained (in mM): NaCl (140), KCl (4), CaCl2
(2), MgCl2 (1), HEPES (10), CdCl2 (0.1) and glucose (10). The pH was adjusted to 7.4 with NaOH, and
osmolarity was adjusted with sucrose to 315 mOsm. The intracellular solution contained (in mM): CsF
(140), EGTA/CsOH (1/5), HEPES (10) and NaCl (10). The pH was adjusted to 7.4 with CsOH and
osmolarity adjusted with sucrose to 320 mOsm. OD1 and GpTx-1 were diluted in EC with the addition
of 0.1% BSA.
Whole-cell patch-clamp experiments were performed at room temperature on a QPatch-16
automated electrophysiology platform (Sophion Bioscience, Ballerup, Denmark) using 16-channel
planar patch chip plates (QPlates; Sophion Bioscience) with a patch hole diameter of 1 µm and a
resistance of 2 ˘ 0.02 MΩ. Cell positioning and sealing parameters were set as follows: positioning
pressure ´60 mbar, minimum seal resistance 0.1 GΩ, holding potential ´100 mV, holding pressure
´20 mbar. Whole-cell currents were filtered at 5 kHz and acquired at 25 kHz.
Cells expressing hNaV1.7 were maintained with a holding potential of ´100 mV between voltage
protocols. Current-voltage (IV) relationships were determined using a family of 500-ms conditioning
pulses from´120 mV to +70 mV in 5-mV steps, followed by depolarization to 0 mV to assess the voltage
dependence of fast inactivation (repetition interval: 20 s). Both peak and late current (10 ms post-peak)
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of the IV family were measured. State-dependence was assessed after a 10-min compound incubation
(˘OD1 300 nM) to ensure steady-state inhibition for each concentration. In order to assess compound
activity at the partially inactivated/open state, a 50-ms depolarization to 0 mV was measured after
a conditioning pulse to ´55 mV for 8 s, with a 50-ms recovery period between (repetition interval
12 s). To assess possible interaction with the voltage sensor domain, a triple-pulse protocol was used,
comprising two steps to 0 mV for 50 ms separated by a strong depolarization step to +200 mV for
50 ms with 20-ms recovery to the ´100-mV holding potential between each step.
4.11. Data Analysis and Statistics
Data were plotted and analyzed using GraphPad Prism (GraphPad Softare, Version 6.0, La Jolla,
CA, USA). Statistical significance was defined as p < 0.05 and was determined by the t-test or one-way
ANOVA with Dunnett’s post-test, as appropriate. Data are expressed as the mean ˘ standard error
of the mean. For electrophysiology experiments, the voltage dependence of steady-state inactivation
was calculated by dividing the amplitude of the test current (I) by the maximal current elicited (Io),
as defined by: INa = I/Io. The voltage-dependence of activation was derived from IV curves after
normalizing for Na+ conductance (GNa) using: GNa = INa/(Vmemb ´Vrev), where Vmemb is the membrane
potential and Vrev is the reversal potential. Steady-state kinetic parameters were obtained by fitting the
data to Boltzmann equations y = bottom + (top ´ bottom)/(1 + exp((V50 ´ x)/slope)). Sophion QPatch
Assay Software (Sophion, Version 5.0, Ballerup, Denmark) was used to determine the time of decay (τ)
for inactivating current using the equation for first-order exponential decay: y = y0 ˆ exp(- k ˆ x) +
yp, where y is current, x is time, y0 is peak current, yp is the plateau and k is the rate constant. τ was
calculated separately for each conditioning potential, defined as 1/k.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/8/3/78/s1.
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